MXPA06013182A - Derivados novedosos de ciclopenta[b] benzofurano y uso de los mismos. - Google Patents

Derivados novedosos de ciclopenta[b] benzofurano y uso de los mismos.

Info

Publication number
MXPA06013182A
MXPA06013182A MXPA06013182A MXPA06013182A MXPA06013182A MX PA06013182 A MXPA06013182 A MX PA06013182A MX PA06013182 A MXPA06013182 A MX PA06013182A MX PA06013182 A MXPA06013182 A MX PA06013182A MX PA06013182 A MXPA06013182 A MX PA06013182A
Authority
MX
Mexico
Prior art keywords
carbon atoms
hydrogen
formula
ethoxy
alkylamino
Prior art date
Application number
MXPA06013182A
Other languages
English (en)
Spanish (es)
Inventor
Joachim Schuhmacher
Thomas Fahrig
Irene Gerlach
Nicole Diedrichs
Jacques Ragot
Kai Thede
Ervin Horvath
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MXPA06013182A publication Critical patent/MXPA06013182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
MXPA06013182A 2004-05-18 2005-05-14 Derivados novedosos de ciclopenta[b] benzofurano y uso de los mismos. MXPA06013182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024504A DE102004024504A1 (de) 2004-05-18 2004-05-18 Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
PCT/EP2005/005298 WO2005113529A2 (de) 2004-05-18 2005-05-14 Neue cylopenta[b]benzofuran-derivate und ihre verwendung

Publications (1)

Publication Number Publication Date
MXPA06013182A true MXPA06013182A (es) 2007-02-14

Family

ID=35207782

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013182A MXPA06013182A (es) 2004-05-18 2005-05-14 Derivados novedosos de ciclopenta[b] benzofurano y uso de los mismos.

Country Status (14)

Country Link
US (1) US8030347B2 (https=)
EP (1) EP1751127B1 (https=)
JP (1) JP2007538031A (https=)
KR (1) KR101215164B1 (https=)
CN (1) CN1989122B (https=)
AU (1) AU2005245104B2 (https=)
BR (1) BRPI0510403A (https=)
CA (1) CA2567404C (https=)
DE (1) DE102004024504A1 (https=)
IL (1) IL179257A (https=)
MX (1) MXPA06013182A (https=)
RU (1) RU2415847C9 (https=)
WO (1) WO2005113529A2 (https=)
ZA (1) ZA200609444B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1693059A1 (en) * 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
EP2457907A1 (en) * 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
EP3755693B1 (en) 2018-02-19 2024-06-12 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
EP3639820A1 (en) 2018-10-16 2020-04-22 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Flavagline derivatives for inhibition of kras oncogene activation
CN110646616B (zh) * 2019-09-05 2023-05-30 桂林理工大学 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法
CN110776486B (zh) * 2019-10-23 2022-05-20 中国药科大学 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用
CA3230542A1 (en) 2021-09-01 2023-03-09 Krishnaraj Rajalingam Novel ras inhibitors
CN116077483A (zh) * 2021-11-05 2023-05-09 上海中医药大学 楝酰胺及其类似物的药物用途
CN115385924B (zh) * 2022-10-06 2023-10-13 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用
WO2024175662A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH Flavagline derivatives as ras inhibitors
JP2026508161A (ja) 2023-02-23 2026-03-10 エスジェーピー バイオテック ゲーエムベーハー 新規ＲＡＳ阻害剤３ａＨ－シクロペンタ［ｂ］ベンゾフラン－３ａ－イル
WO2025092976A1 (zh) * 2023-11-03 2025-05-08 映恩生物制药（苏州）有限公司 蛋白翻译抑制剂
TW202545938A (zh) * 2024-01-16 2025-12-01 大陸商映恩生物製藥（蘇州）有限公司 一種蛋白轉譯抑制劑的偶聯物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191264B (en) * 1984-01-13 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for production of derivatives of 7-oxo-prostacyclin with selective biological effect
KR100381584B1 (ko) * 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE19835325A1 (de) * 1998-08-05 2000-02-10 Bayer Ag Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten
DE19835324A1 (de) * 1998-08-05 2000-02-10 Bayer Ag Cyclopentabenzofuran-Derivate und ihre Verwendung
DE10158561A1 (de) * 2001-11-29 2003-06-12 Bayer Ag Neue Verwendung von Cyclopentabenzofuranen

Also Published As

Publication number Publication date
AU2005245104A1 (en) 2005-12-01
DE102004024504A1 (de) 2006-02-16
CN1989122B (zh) 2013-07-24
ZA200609444B (en) 2008-01-30
RU2006144710A (ru) 2008-06-27
JP2007538031A (ja) 2007-12-27
IL179257A0 (en) 2007-03-08
RU2415847C2 (ru) 2011-04-10
EP1751127B1 (de) 2012-07-11
US20090018113A1 (en) 2009-01-15
EP1751127A2 (de) 2007-02-14
WO2005113529A2 (de) 2005-12-01
KR20070011522A (ko) 2007-01-24
WO2005113529A3 (de) 2006-02-09
US8030347B2 (en) 2011-10-04
KR101215164B1 (ko) 2012-12-24
CA2567404C (en) 2014-04-01
IL179257A (en) 2013-02-28
AU2005245104B2 (en) 2011-07-28
CA2567404A1 (en) 2005-12-01
RU2415847C9 (ru) 2011-08-10
BRPI0510403A (pt) 2007-10-23
CN1989122A (zh) 2007-06-27

Similar Documents

Publication Publication Date Title
KR101215164B1 (ko) 신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도
JP7253640B2 (ja) 複素環化合物およびその用途
JP7408569B2 (ja) 複素環化合物
JP6574918B1 (ja) 複素環化合物およびその用途
JP7379374B2 (ja) 複素環化合物
WO2019057123A1 (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
JP2001505585A (ja) 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
CN115003670A (zh) 杂环化合物
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
JP7592226B1 (ja) 複素環化合物
JP2022064180A (ja) 複素環化合物
CN120641412A (zh) 杂环化合物及其用途
CN110407854B (zh) 新的四环化合物
WO2001083452A1 (en) Novel tricyclic compounds
CN102656162B (zh) (杂环/四氢吡啶)-(哌嗪基)-1-烷酮和(杂环/二氢吡咯烷)-(哌嗪基)-1-烷酮衍生物及其作为p75抑制剂的用途
JP7821946B1 (ja) マクロ環状複素環化合物及びその用途
HK1108885A (en) Novel cylopenta[b]benzofuran derivatives and the utilization thereof
HK40051268A (en) A heterocyclic compound, preparation method therefor, and use
WO2024067676A1 (zh) 作为sumo活化酶抑制剂的化合物
CN113264925A (zh) 一种杂环化合物及其制备方法和用途
HK40057687A (en) Heterocyclic compounds and use thereof

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration